Clinical Trials List
2022-07-01 - 2027-12-31
Phase III
Not yet recruiting2
Recruiting2
Avelumab Master Protocol: An Open-label Continuation Study for Participants Continuing From Pfizer-sponsored Avelumab Clinical Studies.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 張境夫 無
- 余紹銘 無
- Yung-Chang Lin 無
- 沈鼎文 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 徐偉勛 無
- Jih-Hsiang Lee 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chi-Rei Yang 未分科
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
PF-04518600
Utomilumab (PF-05082566)
Dosage Form
Solution for injection
Solution for injection
Dosage
10mg/ml
10mg/ml
Endpoints
Inclution Criteria
Any participant who is receiving study treatment and deriving significant clinical benefit or is in the safety and/or survival follow-up period in a Pfizer-sponsored Avelumab Parent Study.
Participants must agree to follow the reproductive criteria.
Participants must be willing and able to comply with all scheduled visits, treatment plan, and other study procedures.
Exclusion Criteria
Female participants who are pregnant or breastfeeding.
Any medical reason that, in the opinion of the Investigator or Sponsor, precludes the participant from inclusion in the study.
The Estimated Number of Participants
-
Taiwan
7 participants
-
Global
300 participants
